NCT01609348View on ClinicalTrials.gov

Venlafaxine for Depression in Alzheimer's Disease (DIADs-3)

NACompletedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

April 30, 2012

Primary Completion Date

December 31, 2016

Study Completion Date

January 31, 2017

Conditions
Alzheimer's DiseaseDepression
Interventions
DRUG

Placebo

Capsule matching active drug to be taken once a day for 12 weeks

DRUG

Venlafaxine

225 mg daily for 12 weeks

Trial Locations (2)

19611

Reading Hospital, West Reading

21225

Johns Hopkins at Bayview, Baltimore

All Listed Sponsors
lead

Johns Hopkins University

OTHER

NCT01609348 - Venlafaxine for Depression in Alzheimer's Disease (DIADs-3) | Biotech Hunter | Biotech Hunter